Tigermed Consulting kicks off Hong Kong secondary listing

Pharma_drugs_adobe_575x375.jpg
By Jonathan Breen
20 Jul 2020

Shenzhen-listed Hangzhou Tigermed Consulting has caught the attention of international and local investors for its secondary listing on the Hong Kong exchange, set to be worth at least $1bn.

Tigermed is a biopharmaceutical research and development service provider. According to a report by Frost & Sullivan cited in its listing documents, it was the leading contract research organisation (CRO) in China, based on revenue and clinical trials in 2019.

It began pre-marketing to investors on Monday through ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial